Objective To compare adverse event reporting patterns for seven Alzheimer’s disease (AD) drugs (aducanumab, donanemab, lecanemab, donepezil, galantamine, rivastigmine, and memantine) using the FDA Adverse Event Reporting System (FAERS), and to explore potential reporting signals. Methods FAERS reports from the first qu...
Kai Liu, Xiao-Hu Yang, Ling-Ti Kong· Frontiers in Pharmacology· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.